In this presentation, industry experts Suparna Sanyal and Peng Wang from Lonza take you deep into the industrialization of AAV (Adeno-Associated Virus) manufacturing. The session explores two powerful production platforms—Xcite® Transient Transfection and Stable Producer Cell Lines—designed to meet the growing demand for scalable, efficient, and high-quality AAV production. Through detailed case studies and real-world data, the speakers demonstrate how these platforms streamline upstream and downstream processes, enhance packaging efficiency, and support rapid scale-up from shake flask to 250L bioreactors and beyond.
We introduce our proprietary analytics, including advanced 3D digital droplet PCR (ddPCR) techniques that provide comprehensive insights into AAV genome integrity and identity. These tools are critical for ensuring product quality and regulatory compliance, especially as gene therapy products move from development to commercialization. Whether you're working with standard or novel capsids, the Xcite® platform offers flexibility and performance, with titers reaching up to 1E16 VG and packaging efficiencies exceeding 90%.
For developers seeking to reduce cost of goods and improve process robustness, the stable producer cell line platform offers a game-changing alternative. With all AAV components stably integrated into the genome, this system eliminates the need for plasmids and helper viruses, enabling safer, more consistent, and scalable production. The webinar outlines the full development workflow, from DNA sequence to GMP readiness, and shares compelling data from feasibility studies and client case studies.Preview this webinar
Get immediate access to the full webinar by filling out the form on this page.